Wait 12 minutes before moving to the next step
The prevalence of MASLD is increasing in pediatrics and if untreated there will be more metabolic disease burden in adulthood
2 WeightWatchers also still offers its core Points-based programme for people not taking medication, and it can be used alongside the GLP-1 programme
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
Patients interested in this peptide can explore ipamorelin therapy at our Miami clinic for more details